Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole

References

• Agarwal S, Hartz AM, Elmquist WF, Bauer B. (2011). Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des 17:2793–802
   PubMed Web of Science ®Google Scholar
• Agarwal S, Sane R, Gallardo JL, et al. (2010). Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 334:147–55
   PubMed Web of Science ®Google Scholar
• Bleakley S. (2012). Identifying and reducing the risk of antipsychotic drug interactions. Progr Neurol Psychiatry 16:20–4
   Google Scholar
• Boulton DW, Kollia G, Mallikaarjun S, et al. (2008). Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinet 47:475–85
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company and Otsuka America Pharmaceutical Inc. AbilifyTM (aripiprazole) tablets prescribing information. Available at: http://www.abilify.com
   Google Scholar
• Broekema WJ, De Groot IW, Van Harten PN. (2007). Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics—a European study. Pharm World Sci 29:126–30
   Google Scholar
• Burris KD, Molski TF, Xu C, et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381–9
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• De Vries NA, Zhao J, Kroon E, et al. (2007). P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 13:6440–9
   PubMed Web of Science ®Google Scholar
• Doran A, Obach RS, Smith BJ, et al. (2005). The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165–74
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36
   PubMed Web of Science ®Google Scholar
• Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ, et al. (2010). Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol 79:921–5
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, Von Richter O, et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–8
   PubMed Web of Science ®Google Scholar
• Ieiri I. (2012). Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet 27:85–105
   PubMed Web of Science ®Google Scholar
• Kirschbaum KM, Uhr M, Holthoewer D, et al. (2010). Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 59:474–9
   PubMed Web of Science ®Google Scholar
• Kodaira H, Kusuhara H, Ushiki J, et al. (2010). Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 333:788–96
   PubMed Web of Science ®Google Scholar
• Langan J, Shajahan P. (2010). Antipsychotic polypharmacy: review of mechanisms, mortality and management. The Psychiatrist 34:58–62
   Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. (2004). Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 44:179–87
   PubMed Web of Science ®Google Scholar
• Mitchell P. (2000). Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol 49:303–12
   PubMed Web of Science ®Google Scholar
• Nagasaka Y, Oda K, Iwatsubo T, et al. (2012). Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood–brain barrier. Biopharm Drug Dispos 33:304–15
   PubMed Web of Science ®Google Scholar
• Nakagami T, Yasui-Furukori N, Saito M, et al. (2005). Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 78:43–51
   PubMed Web of Science ®Google Scholar
• Polli JW, Olson KL, Chism JP, et al. (2009). An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 37:439–42
   PubMed Web of Science ®Google Scholar
• Salphati L, Lee LB, Pang J, et al. (2010). Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 38:1422–6
   PubMed Web of Science ®Google Scholar
• Schmitt U, Abou El-Ela A, Guo LJ, et al. (2006). Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J Neural Transm 113:787–801
   PubMed Web of Science ®Google Scholar
• Wang J, Zhu H, Markowitz J, et al. (2008). Antipsychotic drugs inhibit the function of breast cancer resistance protein. Basic Clin Pharmacol Toxicol 103:336–41
   PubMed Web of Science ®Google Scholar
• Wang JS, Zhu HJ, Donovan JL, et al. (2009). Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr Res 110:90–4
   PubMed Web of Science ®Google Scholar
• Wang JS, Zhu HJ, Markowitz JS, et al. (2006). Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 187:415–23
   PubMed Web of Science ®Google Scholar